Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Insilico, newly listed in Hong Kong, strikes up to $888M oncology deal with Servier

By Brian Buntz | January 4, 2026

Image courtesy of Insilico Medicine

Days after going public on the Hong Kong Stock Exchange, Insilico Medicine has struck a multi-year oncology drug discovery partnership with France’s Servier worth up to $888 million. The collaboration will focus on developing oncology therapies, by combining Insilico’s AI-driven drug discovery platforms with Servier’s global expertise in cancer drug development.

 Insilico pointed to its existing oncology pipeline, including programs already in Phase I trials, as evidence it can deliver drug candidates beyond the concept stage. Servier will apply its oncology development and commercialization capabilities to any candidates that emerge from the collaboration.

The Servier deal’s economics follow a familiar template for AI-driven drug discovery partnerships: roughly $32 million in upfront and near-term R&D payments against an $888 million headline, about 3.6% front-loaded. That ratio sits squarely within the 2–5% band that has become standard for discovery-platform collaborations, where the bulk of value is pushed into development and commercial milestones that rarely pay out in full. Recent deals from Exscientia, Schrödinger and Isomorphic Labs show similar structures, though there are signs the absolute dollar amounts upfront are creeping higher even as headline totals balloon.

Zhavoronkov described the partnership as another step toward “pharmaceutical superintelligence, where AI agents could actually make decisions and design experiments.” It’s a vision he’s championed for years. Meanwhile, the pharma industry’s enthusiasm for AI is more bifurcated since the 2023 boom: pharma dealmaking has stayed aggressive, while public-market patience has worn thin.

AI drug discovery deal comparison table

Deal Announced Cash Upfront “Up to” Value (ex-royalties) % Upfront Type Notes
AstraZeneca / CSPC Jun 2025 $110M $5.33B ($110M + $1.62B dev + $3.6B sales) 2.1% Discovery platform AI-driven dual-engine platform; immunology focus
Schrödinger / BMS Nov 2020 $55M $2.755B ($55M + $2.7B) 2.0% Discovery platform Physics-based; oncology, immunology, neuro
Sanofi / Earendil Labs Apr 2025 $125M $1.845B ($125M + $1.72B) 6.8% Asset license Two named bispecifics; includes $50M near-term
Isomorphic Labs / Lilly Jan 2024 $45M $1.745B ($45M + $1.7B) 2.6% Discovery platform AlphaFold spinout; small molecules
Insilico / Sanofi Nov 2022 Up to $21.5M $1.22B ($21.5M + $1.2B) 1.8% Discovery platform 6 targets; upfront includes nomination fees
Exscientia / BMS May 2021 Up to $50M ~$1.2B+ ~4.2% Discovery platform Multi-target; near-term milestones up to $125M
Exscientia / Merck KGaA Sep 2023 $20M $694M ($20M + $674M) 2.9% Discovery platform 3 initial programs
Isomorphic Labs / Novartis Jan 2024 $37.5M $1.24B ($37.5M + $1.2B) 3.0% Discovery platform 3 undisclosed targets
Incyte / Genesis 2025 $30M ~$620M (2 targets) 4.8% Discovery platform $295M per target in milestones
Menarini / Insilico (KAT6) Jan 2024 $12M >$500M ≤2.4% Asset license Preclinical KAT6 inhibitor; breast cancer
Menarini / Insilico (#2) Jan 2025 $20M >$550M ≤3.6% Asset license Second oncology asset
Insilico / Servier Jan 2026 $32M $888M 3.6% Discovery platform Multi-target oncology

 


Filed Under: machine learning and AI
Tagged With: AI driven drug design, AI drug discovery, artificial intelligence in pharma, biotech IPO, development milestones, drug discovery platforms, Hong Kong Stock Exchange, Insilico Medicine, milestone based deals, oncology drug discovery, oncology pipeline, pharma partnerships, pharmaceutical collaborations, Phase I clinical trials, Servier, upfront payments
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
‘A plate of spaghetti’: Talus Bio boasts 5,000-fold faster drug screening by skipping protein folding
How Sheba Medical Center became OpenAI’s first international hospital partner
Schrödinger-BMS collaboration centers on Bunsen for trillion-scale computational drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE